Silibinin
chemical compound
Silibinin (INN), also known as silybin (both from Silybum, the generic name of the plant from which it is extracted), is the major active constituent of silymarin, a standardized extract of the milk thistle, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silychristin, silidianin, and others. Silibinin itself is a mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio.
In some European countries, silibinin is available as part of the silymarin extract for oral use and as a water solution containing the dihemisuccinate disodium salt for intravenous injection. The extract is also available in other regions as a dietary supplement.
Medical uses
Amanita poisoning
Intravenous silibinin (specifically the water-soluble form of silibinin-C-2',3-dihydrogen succinate disodium [silibinin dihemisuccinate disodium], trade name Legalon) is approved in Europe for Amanita poisoning. It is not approved in the US but can be obtained through the Expanded Access IND mechanism. This form is not found on the European Medicines Agency approved drug list, which means that if it is approved in Europe, it is only approved by some specific national agencies. It is not found on the list of Italian Medicines Agency.
Other hepatoprotective uses
In 2012, the dihemisuccinate disodium compound received Orphan Medicinal Product Designation for the prevention of recurrent hepatitis C in liver transplant recipients by the European Commission.
Oral products containing silibinin is approved in some EU countries as adjunctive therapy in chronic hepatitis and cirrhosis.
“Silibinin” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Silibinin, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Silibinin” is worth following because a concise public description often conceals a longer documentary argument. Here, Silibinin, chemical and compound provides the most credible route into that argument.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Aug 11, 2026. The linked authority identifier is Q425702. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2012.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Silibinin”, its source revision and the description used here.
- Expand the search: follow Silibinin primary sources, Silibinin archive and Silibinin research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Silibinin”?
- Is the terminology current, historical or disputed?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Silibinin” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.